Influence of food on the pharmacokinetic profile of fesoterodine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 6, 2009, Pages 384-390

  Malhotra, Bimal ^a   Sachse, R ^b   Wood, N ^a  

^a PFIZER INC   (United States)

^b Schwarz Pharma AG   (Germany)

Author keywords

Antimuscarinic; Cytochrome P450; Food; Pharmacokinetics

Indexed keywords

FESOTERODINE;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; NAUSEA; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; VOMITING; XEROSTOMIA;

EID: 67649979920     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47384     Document Type: Article

References (19)

1. Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997; 35: 287-295.
2. Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol. 2002; 365: 110.
3. Chapple C, van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Massow U, Wang J, Brodsky M. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007; 52: 1204-1212.
4. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future. 2004; 29: 715-720.
5. Food and Drug Administration. Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/cder/guidance/5194fnl.htm. Accessed November 25, 2008.
6. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50: 1306-1315.
7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288: 462-467.
8. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008; 46: 556-563.
9. Malhotra B, Gandelman K, Sachse R, Wood N. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol. 2009; Epub ahead of print.
10. Michel M. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008; 9: 1787-1796.
11. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother. 2000; 11: 13-27.
12. Nilvebrant L. Clinical experiences with tolterodine. Life Sci. 2001; 68: 2549-2556.
13. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007; 178: 2488-2494.
14. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001; 40: 227-235.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487-497.
16. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006; 67: 275-280.
17. Sachse R, Cawello W, Haag MC, Horstmann R. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine [abstract]. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367: 446.
18. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-336.
19. Toviaz® (fesoterodine fumarate). Full Prescribing Information, Pfizer Inc., New York, NY, 2007.